- Join / Support
- Log In
- Room Hire
- Member's Area
- Youth Activities
- Local Studies
15 June 2018
Dr Matthew Lloyd Department of Pharmacy and Pharmacology University of Bath
Modern medicine often exploits differences between diseased and ‘normal’ cells to develop new treatments. Levels of the protein AMACR are increased in prostate and other cancers, and these increased levels appear to drive aggressive behaviours by the cancer. Studies have suggested that stopping AMACR from working could be an effective way of treating these cancers. This talk will describe the general approaches to
identifying and developing a new treatment and the investigation of new treatments based on blocking AMACR function, illustrating these approaches.
This work has been funded by Prostate Cancer UK, Cancer Research UK and others.